Acute nonlymphocytic leukemia following short-term, intermittent, intravenous cyclophosphamide treatment of lupus nephritis.
Intermittent intravenous cyclophosphamide therapy has been shown to be effective in the management of lupus nephritis. There have been no reports of malignancies associated with such treatment regimens. We describe a patient who developed acute nonlymphocytic leukemia after receiving a total dose of 4 gm of cyclophosphamide over a 1-year period.
Gibbons
R B
RB
Rheumatology Section, Saint Joseph Hospital, Denver, Colorado 80218.
Westerman
E
E
D000368:Aged; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D008181:Lupus Nephritis / Q000188:drug therapy*; D011241:Prednisone / Q000008:administration & dosage; D012307:Risk Factors
D003520:Cyclophosphamide; D011241:Prednisone